Zhao Xiaotong, Yang Ziling, Zheng Tianjiao, Zeng Mengyao, Lin Xiaowen, Chen Huixin, Zheng Weiqin, Peng Sizheng, Li Shibo, Song Tao, Sun Yuhui
Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Cancer Med. 2025 Mar;14(5):e70755. doi: 10.1002/cam4.70755.
A growing number of systematic bioinformatics analyses were conducted to investigate the mechanism of interaction between long non-coding RNA (lncRNA) and endometrial carcinoma (EC) to predict the prognosis. However, there is no evidence-based evidence that abnormal lncRNA expression is strongly associated with the pathological characteristics and prognosis of EC patients. In this meta-analysis, we systematically evaluated the relationship between upregulated lncRNA expression levels and clinicopathological features, five-year survival rate, and progression-free survival (PFS).
A systematic search was performed across seven reputable databases, namely the China National Knowledge Infrastructure, Wanfang, Wipu, PubMed, Web of Science, Cochrane Library, and Embase, encompassing the period from the inception of each database until November 27, 2022. Heterogeneity among the studies was assessed through the application of Cochran's Q and I statistics. All statistical analyses were conducted using Stata 14.0 software.
This study encompassed 30 clinical studies, involving a total of 2469 EC patients, and examined the expression of 24 lncRNAs, which were upregulated in EC samples. EC patients with higher expression of lncRNAs showed a later FIGO stage (OR = 1.94, 95% CI: 1.29 ~ 2.91), a poorer histological grade (OR = 3.40, 95% CI: 2.51 ~ 4.60), earlier deep myometrial invasion (OR = 2.57, 95% CI: 1.94 ~ 3.41), a higher likelihood of lymphatic vascular space infiltration (OR = 2.86, 95% CI: 1.15 ~ 7.14), an increased propensity for lymph node metastasis (OR = 2.89, 95% CI: 1.82 ~ 4.60), and a greater likelihood of distant metastasis (OR = 2.39, 95% CI: 1.33 ~ 4.30). All of these were statistically significant (p < 0.05). Furthermore, EC patients with a higher expression level of lncRNAs were significantly associated with five-year survival (p < 0.05) and PFS (p < 0.05).
High expression levels of upregulated lncRNAs in EC patients are associated with unfavorable clinicopathological features, a poor five-year survival rate, and PFS. It serves as a detrimental prognostic factor and might be a biomarker and therapeutic target for EC.
越来越多的系统性生物信息学分析旨在研究长链非编码RNA（lncRNA）与子宫内膜癌（EC）之间的相互作用机制，以预测预后。然而，尚无循证依据表明lncRNA异常表达与EC患者的病理特征和预后密切相关。在这项荟萃分析中，我们系统评估了lncRNA表达水平上调与临床病理特征、五年生存率及无进展生存期（PFS）之间的关系。
在七个著名数据库中进行了系统检索，分别为中国知网、万方、维普、PubMed、Web of Science、Cochrane图书馆和Embase，检索时间跨度为各数据库建库至2022年11月27日。通过应用Cochran's Q和I统计量评估研究间的异质性。所有统计分析均使用Stata 14.0软件进行。
本研究纳入30项临床研究，共涉及2469例EC患者，检测了24种在EC样本中表达上调的lncRNA。lncRNA表达较高的EC患者国际妇产科联盟（FIGO）分期较晚（OR = 1.94，95%可信区间：1.29至2.91）、组织学分级较差（OR = 3.40，95%可信区间：2.51至4.60）、肌层浸润较早（OR = 2.57，95%可信区间：1.94至3.41）、淋巴血管间隙浸润可能性较高（OR = 2.86，95%可信区间：1.15至7.14）、淋巴结转移倾向增加（OR = 2.89，95%可信区间：1.82至4.60）以及远处转移可能性更大（OR = 2.39，95%可信区间：1.33至4.30）。所有这些差异均具有统计学意义（p < 0.05）。此外，lncRNA表达水平较高的EC患者与五年生存率（p < 0.05）及PFS（p < 0.05）显著相关。
EC患者中上调的lncRNA高表达水平与不良临床病理特征、较差的五年生存率及PFS相关。它是一个不利的预后因素，可能是EC的生物标志物和治疗靶点。
